MODERN APPROACHES TO DETECTING EARLY SUBCLINICAL CARDIOTOXICITY INDUCED BY CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER

In recent decades, developed countries of the world have made progress in the treatment of breast cancer, both because of the early detection of cancer and the use of modern methods of treatment (target therapy and chemotherapy, radiation therapy and surgical treatment). Due to this, the time of disease-free course of cancer and the duration of life of patients have increased. However, a number of antitumor drugs have cardiotoxicity [1]. It is shown that cardiovascular diseases are the second leading cause of death among women who have undergone breast cancer [27]. Reduction of systolic function of the heart is the most common manifestation of cardiotoxicity of antitumor therapy [7]. Other manifestations of cardiotoxicity include arterial hypertension (AH), acute coronary syndrome, arrhythmias and thromboses. In recent years, methods such as electrocardiography (ECG); echocardiography (EchoCG) with the classical definition of the left ventricular ejection fraction (LVEF) by the method of Simpson's biplane and the global longitudinal strain of the left ventricular (GLS) using data from the 2D Speckle Tracking Imaging; determination of the level of biomarkers of myocardial damage and magnetic resonance imaging (MRI) of the heart have been used to detect the cardiotoxicity of antitumor therapy. Thus, the early diagnosis and timely detection of cardiotoxic effects of antitumor drugs are among the tasks of cardiooncology - an area in medicine formed in recent years [1].

cardiooncology, arterial hypertension, cardiotoxicity, technology speckle tracking, chemotherapy, breast cancer

1. Yuand Jones. Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures. Cardio-Oncology. 2016;2:1 DOI 10.1186/s40959-016-0011-5

2. Chazova I.E., Oshchepkova E.V., Kantorova A.Yu. Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy. Terarkh. 2015;87(9): 4-10. doi: 10.17116/terarkh20158794-10 [in Russian]

3. Avalyan A.A., Kirillova M.Yu., Shitov V.N., Oshchepkova Ye.V., Saidova M.A., Stenina M.B., Chazova I.Ye. Markers of early cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood pressure level. Systemic hypertension 2017; 14 (3): 21–27. DOI: 10.26442/2075-082X_14.3.21-27 [in Russian]

4. Fausto Pizzino, Giampiero Vizzari, Charles A. Bomzeretall. Diagnosis of Chemotherapy-Induced Cardiotoxicity. Journal of Patient-Centered Research and Reviews 8-13-2014: 121-127

5. D. Bovelli, G. Plataniotis, F. Roila. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology. 21 (Supplement 5): 277–282, 2010

6. Maria Florescu et all. Chemotherapy-inducedCardiotoxicity. A Journal of Clinical Medicine 2013; 8(1): 59-67

7. Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Mun˜oz, Victor Aboyans, Riccardo Asteggiano et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016,August 26.

8. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associatedwith tyrosine kinase inhibitors. Oncologist 2013;18:900–908

9. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am CollCardiol. 2009;53:2231–2247

10. Daher IN, Kim C, Saleh RR, Plana JC, Yusuf SW, Banchs J. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospectiveevaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography. 2011;28:1061-7.

11. Juan Carlos Plana et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am SocEchocardiogr. 2014;27:911-39

12. Sergio Mondillo, Maurizio Galderisi, Donato Mele, Matteo Cameli, MD et al. Speckle-Tracking Echocardiography: A New Technique for Assessing Myocardial Function. J Ultrasound Med. 2011; 30:71–8

13. Cardinale D, Colombo A,Lamantia G. et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am CollCardiol. 2010;55:213–20

14. Stoodley PW, Richards DA, Boyd A, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging. 2013 Mar;14(3): 228-34

15. Anita Boyd, Paul Stoodley, David Richards, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study- PLoS One. 2017 Apr 13;12(4):e0175544; 15.

16. Moazeni et al Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient speci c care. Clin Trans Med (2017) 6:17 DOI 10.1186/s40169-017-0148-3

17. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am CollCardiol 63(8):809–816

18. Ciro Santoro1 et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancerpatients: a balance with feasibility. European Heart Journal – Cardiovascular Imaging, Volume 18, Issue 8, 2017, Pages 930–936, doi.org/10.1093/ehjci/jex033

19. Paaladinesh Thavendiranathan et al. Cardiac MRI in the Assessment of Cardiac Injury and Toxicity

20. From Cancer Chemotherapy. A Systematic Review. CircCircCardiovasc Imaging. 2013;6:1080-1091, DOI:10.1161/CIRCIMAGING.113.000899

21. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291(20):2441-7.

22. Chazova I.Ye., Zhernakova Yu.V., Oshchepkova E.V. The prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Cardiology. 2014; 10: 4-12 [in Russian]

23. Pedro Veronese, Denise Tessariol Hachul, Mauricio Ibrahim Scanavacca et al. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLOS ONE. 2018; 2-10. doi.org/10.1371/journal.pone.0196763

24. Ranpura V, Pulipati B, Chu D, Zhu X, Whu S. Increase risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23(5):460-8.

25. Feola M, Garrone O, Occelli M et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 2011;148(2):194–198. doi: 10.1016/j.ijcard.2009.09.564

26. Chazova I.Ye. Tyulyandin S.A., Vitsenya M.V. et al. A guide to the diagnosis, prevention and treatment of cardiovascular complications of antitumor therapy. Part I. Systemic hypertension. 2017; 14 (3); 6-20 [in Russian]

27. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby Metal. Cardiac dysfunction in the trastuzumab clinical trials experience. J ClinOncol. 2002 Mar 1;20 (5):1215–21

28. M.A. Nicolazzi, A. Carnicelli, M. Fuorlo et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. European Review for Medical and Pharmacological Sciences 2018; 22: 2175-2185